TY  - JOUR
AU  - Pelgrim, Teuntje A. D.
AU  - Philipsen, Alexandra
AU  - Young, Allan H.
AU  - Juruena, Mario
AU  - Jimenez, Ester
AU  - Vieta, Eduard
AU  - Jukić, Marin
AU  - Van der Eycken, Erik
AU  - Heilbronner, Urs
AU  - Moldovan, Ramona
AU  - Kas, Martien J. H.
AU  - Jagesar, Raj R.
AU  - Nöthen, Markus M.
AU  - Hoffmann, Per
AU  - Shomron, Noam
AU  - Kilarski, Laura L
AU  - van Amelsvoort, Thérèse
AU  - Campforts, Bea
AU  - van Westrhenen, Roos
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5548
AB  - (1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. (2) Methods This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. (3) Conclusions This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines.
PB  - MDPI
T2  - Pharmaceuticals
T1  - A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study
VL  - 17
IS  - 2
SP  - 151
DO  - 10.3390/ph17020151
ER  - 

@article{
author = "Pelgrim, Teuntje A. D. and Philipsen, Alexandra and Young, Allan H. and Juruena, Mario and Jimenez, Ester and Vieta, Eduard and Jukić, Marin and Van der Eycken, Erik and Heilbronner, Urs and Moldovan, Ramona and Kas, Martien J. H. and Jagesar, Raj R. and Nöthen, Markus M. and Hoffmann, Per and Shomron, Noam and Kilarski, Laura L and van Amelsvoort, Thérèse and Campforts, Bea and van Westrhenen, Roos",
year = "2024",
abstract = "(1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. (2) Methods This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. (3) Conclusions This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines.",
publisher = "MDPI",
journal = "Pharmaceuticals",
title = "A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study",
volume = "17",
number = "2",
pages = "151",
doi = "10.3390/ph17020151"
}

Pelgrim, T. A. D., Philipsen, A., Young, A. H., Juruena, M., Jimenez, E., Vieta, E., Jukić, M., Van der Eycken, E., Heilbronner, U., Moldovan, R., Kas, M. J. H., Jagesar, R. R., Nöthen, M. M., Hoffmann, P., Shomron, N., Kilarski, L. L., van Amelsvoort, T., Campforts, B.,& van Westrhenen, R.. (2024). A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. in Pharmaceuticals
MDPI., 17(2), 151.
https://doi.org/10.3390/ph17020151

Pelgrim TAD, Philipsen A, Young AH, Juruena M, Jimenez E, Vieta E, Jukić M, Van der Eycken E, Heilbronner U, Moldovan R, Kas MJH, Jagesar RR, Nöthen MM, Hoffmann P, Shomron N, Kilarski LL, van Amelsvoort T, Campforts B, van Westrhenen R. A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. in Pharmaceuticals. 2024;17(2):151.
doi:10.3390/ph17020151 .

Pelgrim, Teuntje A. D., Philipsen, Alexandra, Young, Allan H., Juruena, Mario, Jimenez, Ester, Vieta, Eduard, Jukić, Marin, Van der Eycken, Erik, Heilbronner, Urs, Moldovan, Ramona, Kas, Martien J. H., Jagesar, Raj R., Nöthen, Markus M., Hoffmann, Per, Shomron, Noam, Kilarski, Laura L, van Amelsvoort, Thérèse, Campforts, Bea, van Westrhenen, Roos, "A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study" in Pharmaceuticals, 17, no. 2 (2024):151,
https://doi.org/10.3390/ph17020151 . .

TY  - JOUR
AU  - Stanić, Dušanka
AU  - Oved, Keren
AU  - Israel-Elgali, Ifat
AU  - Jukić, Marin
AU  - Batinić, Bojan
AU  - Puškaš, Nela
AU  - Shomron, Noam
AU  - Gurwitz, David
AU  - Pešić, Vesna
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3883
AB  - Intranasal treatment with oxytocin showed beneficial effects in post-traumatic stress disorder and autism spectrum disorders; however, it was not investigated as much in depression. Keeping in mind the favorable effects of oxytocin on animal models of anxiety and depression, we postulated that synergy between prescribed first choice drugs, selective serotonin reuptake inhibitors (SSRIs) and oxytocin could improve the treatment outcome compared with SSRI monotherapy. Our previous in vitro genome-wide transcriptomic study on human lymphoblastoid cell lines exposed to paroxetine resulted in increase of integrin β3 (ITGB3) gene expression, and further, ITGB3/CHL1 expression ratio was hypothesized to influence the sensitivity to SSRIs. The aim of this report was to explore molecular mechanisms behind the antidepressant-like oxytocin effect, alone and in synergy with citalopram, on behavioral and molecular level in corticosterone treated rats, a paradigm used to model anxiety and depression in animals. Oxytocin treatment (1) ameliorated corticosterone-induced reduction of neurogenesis and number of parvalbumin-positive interneurons in the hippocampal CA1 region, (2) enhanced anxiolytic- and antidepressant-like effects of citalopram in the open field test, and (3) the SSRI/oxytocin synergy persisted in reversing the reduction of the Itgb3 gene expression and increased Itgb3/Chl1 ratio in the prefrontal cortices. These results support the existence of synergy between citalopram and oxytocin in reversing the molecular and behavioral changes induced by corticosterone treatment and point to possible molecular mechanisms behind antidepressant-like effect of oxytocin.
PB  - Elsevier Ltd
T2  - Psychoneuroendocrinology
T1  - Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy
VL  - 129
DO  - 10.1016/j.psyneuen.2021.105234
ER  - 

@article{
author = "Stanić, Dušanka and Oved, Keren and Israel-Elgali, Ifat and Jukić, Marin and Batinić, Bojan and Puškaš, Nela and Shomron, Noam and Gurwitz, David and Pešić, Vesna",
year = "2021",
abstract = "Intranasal treatment with oxytocin showed beneficial effects in post-traumatic stress disorder and autism spectrum disorders; however, it was not investigated as much in depression. Keeping in mind the favorable effects of oxytocin on animal models of anxiety and depression, we postulated that synergy between prescribed first choice drugs, selective serotonin reuptake inhibitors (SSRIs) and oxytocin could improve the treatment outcome compared with SSRI monotherapy. Our previous in vitro genome-wide transcriptomic study on human lymphoblastoid cell lines exposed to paroxetine resulted in increase of integrin β3 (ITGB3) gene expression, and further, ITGB3/CHL1 expression ratio was hypothesized to influence the sensitivity to SSRIs. The aim of this report was to explore molecular mechanisms behind the antidepressant-like oxytocin effect, alone and in synergy with citalopram, on behavioral and molecular level in corticosterone treated rats, a paradigm used to model anxiety and depression in animals. Oxytocin treatment (1) ameliorated corticosterone-induced reduction of neurogenesis and number of parvalbumin-positive interneurons in the hippocampal CA1 region, (2) enhanced anxiolytic- and antidepressant-like effects of citalopram in the open field test, and (3) the SSRI/oxytocin synergy persisted in reversing the reduction of the Itgb3 gene expression and increased Itgb3/Chl1 ratio in the prefrontal cortices. These results support the existence of synergy between citalopram and oxytocin in reversing the molecular and behavioral changes induced by corticosterone treatment and point to possible molecular mechanisms behind antidepressant-like effect of oxytocin.",
publisher = "Elsevier Ltd",
journal = "Psychoneuroendocrinology",
title = "Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy",
volume = "129",
doi = "10.1016/j.psyneuen.2021.105234"
}

Stanić, D., Oved, K., Israel-Elgali, I., Jukić, M., Batinić, B., Puškaš, N., Shomron, N., Gurwitz, D.,& Pešić, V.. (2021). Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. in Psychoneuroendocrinology
Elsevier Ltd., 129.
https://doi.org/10.1016/j.psyneuen.2021.105234

Stanić D, Oved K, Israel-Elgali I, Jukić M, Batinić B, Puškaš N, Shomron N, Gurwitz D, Pešić V. Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. in Psychoneuroendocrinology. 2021;129.
doi:10.1016/j.psyneuen.2021.105234 .

Stanić, Dušanka, Oved, Keren, Israel-Elgali, Ifat, Jukić, Marin, Batinić, Bojan, Puškaš, Nela, Shomron, Noam, Gurwitz, David, Pešić, Vesna, "Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy" in Psychoneuroendocrinology, 129 (2021),
https://doi.org/10.1016/j.psyneuen.2021.105234 . .